The eIF2-alpha kinase HRI: a potential target beyond the red blood cell.

The eIF2-alpha kinase HRI: a potential target beyond the red blood cell.
复制标题

DOI:
10.1080/14728222.2017.1397133
复制
发表时间:
2017-12
影响因子:
5.8
通讯作者:
Aktas BH
Aktas BH
中科院分区:
医学2区
文献类型:
--
作者:
Burwick N;Aktas BH

文献摘要

参考文献

被引文献

相似文献

EIF2α激酶血红素调节抑制物(HRI)是四种已知的激酶之一,它能使eIF2mRNA磷酸化以响应各种细胞应激源,从而减少三元复合体的形成和α翻译的减弱。尽管HRI在红系祖细胞中作为血红素感受器的作用广为人知,但药物激活HRI已被证明在广泛的肿瘤亚型中具有抗癌活性。在这里,HRI激活剂作为新的癌症治疗方法的潜力被探索。我们提供了eIF2信号通路的一般介绍,并特别回顾了红系和非红系细胞中eIF2α激酶HRI的数据。我们回顾了在癌症中靶向eIF2信号的各个方面,并强调了使用HRI激活剂对抗肿瘤细胞的有前景的数据。在体内,HRI的药理激活作为一种单一的药物抑制肿瘤生长,没有明显的毒性。HRI激活剂能够提供直接和持续的eIF2α磷酸化,而不会诱导氧化应激或广泛的eIF2α激酶激活,这可能对耐受性特别有利。与现有疗法的联合治疗可能会进一步增强抗癌活性,以克服疾病抵抗力。
The eIF2α kinase heme-regulated inhibitor (HRI) is one of four well-described kinases that phosphorylate eIF2α in response to various cell stressors, resulting in reduced ternary complex formation and attenuation of mRNA translation. Although HRI is well known for its role as a heme sensor in erythroid progenitors, pharmacologic activation of HRI has been demonstrated to have anti-cancer activity across a wide range of tumor sub-types. Here, the potential of HRI activators as novel cancer therapeutics is explored. We provide an introduction to eIF2 signaling pathways in general, and specifically review data on the eIF2α kinase HRI in erythroid and non-erythroid cells. We review aspects of targeting eIF2 signaling in cancer and highlight promising data using HRI activators against tumor cells. Pharmacologic activation of HRI inhibits tumor growth as a single agent without appreciable toxicity in vivo. The ability of HRI activators to provide direct and sustained eIF2α phosphorylation without inducing oxidative stress or broad eIF2α kinase activation may be especially advantageous for tolerability. Combination therapy with established therapeutics may further augment anti-cancer activity to overcome disease resistance.
DOI: 10.1182/blood-2013-03-491043
发表时间: 2013-07-25
期刊: BLOOD
影响因子: 20.3
作者:
Hahn, Cynthia K.;Lowrey, Christopher H.
通讯作者: Lowrey, Christopher H.
DOI: 10.1101/cshperspect.a013706
发表时间: 2012-07-01
影响因子: 7.2
作者:
Dever TE;Green R
通讯作者: Green R
DOI: 10.1126/science.aaa4484
发表时间: 2015-04-10
期刊: Science (New York, N.Y.)
影响因子: --
作者:
Das I;Krzyzosiak A;Schneider K;Wrabetz L;D'Antonio M;Barry N;Sigurdardottir A;Bertolotti A
通讯作者: Bertolotti A
DOI: 10.18632/oncotarget.1186
发表时间: 2013-10
期刊: Oncotarget
影响因子: --
作者:
Aktas BH;Qiao Y;Ozdelen E;Schubert R;Sevinc S;Harbinski F;Grubissich L;Singer S;Halperin JA
通讯作者: Halperin JA
DOI: 10.1074/jbc.273.48.32340
发表时间: 1998-11-27
影响因子: 4.8
作者:
Berlanga, JJ;Herrero, S;de Haro, C
通讯作者: de Haro, C